<DOC>
	<DOC>NCT00444535</DOC>
	<brief_summary>This study will examine the efficacy and safety of lapatinib and bevacizumab in patients with ErbB2-overexpressing breast cancer.</brief_summary>
	<brief_title>Lapatinib and Bevacizumab for Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<criteria>Inclusion criteria: Females that are at least 18 years of age. Women of childbearing potential must have a negative serum pregnancy test at screening. Documented evidence of HER2overexpressing unresectable or metastatic breast cancer. Disease may/may not have been treated in metastatic setting. Subjects are permitted (but not required) to have previouslytreated brain metastases that are stable and asymptomatic. Adequate hepatic, renal and cardiac function ECOG score 01 and a life expectancy of at least 12 weeks. Able to swallow oral medication Signed informed consent Exclusion criteria: Pregnancy Unstable or symptomatic CNS metastases Major surgery within 28 days of enrollment (minor surgery within 7 days). Prior anticancer treatment within 14 days of enrollment, or unresolved treatmentrelated toxicities. A serious nonhealing wound, ulcer, or bone fracture at baseline. Class II, III or IV heart failure as defined by the NYHA functional classification system History of significant vascular disease, arterial thrombosis, unstable INR, hypertensive crisis, or uncontrolled hypertension. History of myocardial infarction, stenting procedure, or angioplasty within 6 months of enrollment. History of abdominal fistulae, gastrointestinal perforation, or intraabdominal abscess within 6 months of enrollment. History of malabsorption syndrome, ulcerative colitis, or bowel obstruction. Proteinuria Requires concurrent anticancer treatment or investigational treatment. Known hypersensitivity to either study medication Received investigational treatment within 28 days or 5 halflives, whichever is longer Concurrent disease or circumstances that would lead the investigator would consider the subject an inappropriate candidate for the study Requires medication that has been excluded during study participation</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>VEGF</keyword>
	<keyword>Tyrosine kinase</keyword>
	<keyword>ErbB2</keyword>
	<keyword>Her2-neu</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>EGFR</keyword>
	<keyword>ErbB1</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>lapatinib</keyword>
</DOC>